Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open Label, Dual Cohort Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors

NCT06427057 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT06427057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06427057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open Label, Dual Cohort Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors
Lead sponsor
Tongji Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2024
Completion date
December 1, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

urinary system tumor